Alopecia Universalis and Chronic Graft-Versus-Host Disease Treated With Ruxolitinib

A case study described a man in his 40s with chronic graft-versus-host disease (cGVHD) and alopecia universalis following an allogenic hematopoietic stem cell transplantation. The patient was treated with ruxolitinib, starting at 5 mg every 12 hours and increasing to 10 mg every 12 hours. Over 10 months, the patient showed marked hair regrowth on the scalp and face, as well as improvement in liver function tests and skin cGVHD symptoms. This case suggested that ruxolitinib could be a potential therapy for patients with cGVHD and alopecia universalis, although further studies were needed to confirm these findings.